Johnson & Johnson $JNJ Shares Sold by Strategic Blueprint LLC

Strategic Blueprint LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 15.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,708 shares of the company’s stock after selling 2,579 shares during the quarter. Strategic Blueprint LLC’s holdings in Johnson & Johnson were worth $2,094,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson during the first quarter worth about $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on JNJ. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Royal Bank Of Canada restated an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a report on Friday, October 10th. Finally, Weiss Ratings raised shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $192.31 on Friday. The firm has a 50-day moving average of $181.99 and a two-hundred day moving average of $165.84. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a market cap of $463.15 billion, a P/E ratio of 18.56, a PEG ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.